Full automation of total metabolic tumor volume from FDG-PET/CT in DLBCL for baseline risk assessments
Jemaa S, Paulson J, Hutchings M, Kostakoglu L, Trotman J, Tracy S, de Crespigny A, Carano R, El-Galaly T, Nielsen T, Bengtsson T. Full automation of total metabolic tumor volume from FDG-PET/CT in DLBCL for baseline risk assessments. Cancer Imaging 2022, 22: 39. PMID: 35962459, PMCID: PMC9373298, DOI: 10.1186/s40644-022-00476-0.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaProgression-free survivalOverall survivalFDG-PETUntreated diffuse large B-cell lymphomaHazard ratioHigh-risk DLBCL patientsCentral nervous system relapseLarge B-cell lymphomaMetabolic tumor volumeImaging-based risk factorsB-cell lymphomaEnhanced risk stratificationHigh-risk populationImaging metricsRisk increaseDLBCL patientsFDG-PET/CTSystemic relapseTumor volumeOrgan involvementPrognostic improvementRisk stratificationInvasive proceduresClinical data